Skip Ribbon Commands
Skip to main content
Translate
Translate
menu iconMenu
search iconSearch

UC San Diego and Verizon Team to Improve Tuberculosis Care

 

December 04, 2012  |   

Verizon Foundation to provide grant, in-kind technology solutions to scale up novel approach to TB treatment

As part of an innovative philanthropic health care program targeting reduction of health care disparities in diverse communities around the United States, the Verizon Foundation has provided the University of California, San Diego School of Medicine with a $300,000 grant, as well as important in-kind health information technology solutions.

The support from Verizon will allow researchers from the University to more quickly scale-up a mobile phone-based solution that they developed to overcome the high cost and other barriers to monitoring tuberculosis patients throughout their treatment.  The approach, called “video directly observed therapy,” or VDOT, is headed by Richard Garfein, PhD, MPH, professor in the Division of Global Public Health, Department of Medicine at UC San Diego.

“Based on the results of a successful pilot study involving patients with tuberculosis in San Diego and Tijuana, Mexico, we plan to scale-up this technology so that tuberculosis care providers elsewhere can use the VDOT system,” said Garfein, adding that the hope is to eventually offer this novel way of monitoring TB treatment to patients across the United States and eventually in countries hard-hit by the contagious disease, such as India.

TB is one of the world’s deadliest infectious diseases, currently affecting more than 11 million people worldwide.  Each year, there are approximately 8.8 million new cases reported, resulting in 1.5 million deaths.

“TB can be cured with an antibiotic regimen,” Garfein explained.  “But the biggest problem care givers face, especially in developing countries, is making sure patients are compliant with treatment that takes six months or longer to complete.”

Adherence is critical to ensure that the treatment succeeds, and the patient doesn’t relapse or develop a drug-resistant strain of TB.  Traditionally, health care providers personally observe patients taking their medication – an approach with many barriers, including high cost, human resources and transportation challenges, particularly in rural areas, and making patients feel patronized.

With VDOT, patients are observed for treatment adherence via videos sent on mobile phones.  UC San Diego’s pilot study of 50 patients in San Diego and Tijuana, supported by the National Institutes of Health, resulted in “high adherence and patient satisfaction,” according to Garfein, as well as significant cost and time savings.

The technologies that underlie the VDOT system were developed under the direction of Kevin Patrick, MD, MS, professor of Family and Preventive Medicine and a researcher at the California Institute for Telecommunications and Information Technology (Calit2) at UC San Diego. In addition to the novel video app, VDOT incorporates a customizable patient management system, text messaging and a HIPAA-compliant server environment. With help from the Verizon grant, Garfein, Patrick and colleagues will spend the next six months customizing the software used to record, encrypt, transfer, store and observe patient videos – making it functional for multiple health departments and care providers simultaneously.

“Once we scale up the software, we initially plan to demonstrate that it works with 100 patients in two California health departments,” said Garfein.  Verizon’s in-kind support will include mobile phones, monthly phone service as well as secure IT storage of this health information, using Enterprise Cloud technology provided by Verizon affiliate Terremark Cloud Computing.

If proven successful, this approach could be a cheap and effective way to assure medication adherence in remote areas of India and other countries, where in-person monitoring is very difficult and labor-intensive.

“We are grateful for Verizon’s support in this critical next stage of development,” Garfein said.  “The potential for VDOT to save lives as well as resources domestically and abroad is tremendous.”

# # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu

Related Specialties

Infectious Disease

 



Media Contact

Related News

4/2/2015
Methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant superbug, can cause life-threatening skin, bloodstream and surgical site infections or pneumonia. Researchers at the Univers ...
2/24/2015
Chronic wasting disease (CWD) affects North American elk and deer, but has not been observed in humans. Using a mouse model that expresses an altered form of the normal human prion protein, researcher ...
2/18/2015
Researchers at University of California, San Diego School of Medicine used algae as a mini-factory to produce a malaria parasite protein. The algae-produced protein, paired with an immune-boosting coc ...
2/3/2015
New findings by researchers at the University of California, San Diego School of Medicine open the door to the development of new therapies to block or decrease cognitive decline due to HIV-associated ...
1/12/2015
Pieter Dorrestein, PhD, has been selected to receive the 2015 John Jacob Abel Award in Pharmacology by the American Society for Pharmacology and Experimental Therapeutics (ASPET). Dorrestein is a prof ...
1/5/2015
When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the U ...
12/1/2014
The bacterium Salmonella Typhi causes typhoid fever in humans, but leaves other mammals unaffected. Researchers at University of California, San Diego and Yale University Schools of Medicine now offer ...
11/25/2014
The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs Schoo ...